Investor Centre

Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
Stat background
0.96 GBX Volume: 9,045,986 Market Capitalisation (m) £4.08

TheraCryf plc Full Year Results

29 - May - 2024
Current corporate presentation

Capital Access Group Analyst Research

20 - May - 2024
Capital Access Group has initiated new analyst research on the Company following its recent acquisition of Chronos Therapeutics.

TheraCryf plc - Full Year Results

29 - May - 2024
CEO Dr Huw Jones, CBO Dr Helen Kuhlman and new CFO Toni Haenninen discuss TheraCryf's results for year ending 31st March 2024.

Major Shareholder

Current ShareholderNumber of sharesPercentage holding
J. R. Kight33,100,0007.75%
Rathbones Investment Management Ltd25,789,2466.03%
Octopus Investments21,875,0005.12%
Vulpes Investment Management Pte Ltd20,554,1914.81%
First Equity Limited20,500,0004.80%
Seneca Partners Limited16,301,4563.81%
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 13 June 2024